logo
Send Message
Hefei Home Sunshine Pharmaceutical Technology Co.,Ltd
products
products
Home > products > API Active Pharmaceutical Ingredient > Epalrestat CAS 82159-09-9

Epalrestat CAS 82159-09-9

Product Details

Place of Origin: China

Brand Name: Sunshine

Certification: ISO,COA

Model Number: 82159-09-9

Payment & Shipping Terms

Minimum Order Quantity: Negotiation

Price: Negotiation

Packaging Details: Aluminum Foil Bag, Drum

Delivery Time: 7-15DAY

Payment Terms: L/C,D/A,D/P,T/T,Western Union,MoneyGram

Supply Ability: G,KG,TON

Get Best Price
Highlight:
Appearance::
Deep Red Acicular Crystal
CAS NO::
82159-09-9
Molecular Formula::
C15H13NO3S2
Molecular Weight::
319.39900
EINECS NO::
675-018-0
MDL NO::
MFCD00865484
Appearance::
Deep Red Acicular Crystal
CAS NO::
82159-09-9
Molecular Formula::
C15H13NO3S2
Molecular Weight::
319.39900
EINECS NO::
675-018-0
MDL NO::
MFCD00865484
Epalrestat CAS 82159-09-9

Product Description:

Product Name: Epalrestat CAS NO: 82159-09-9


Synonyms:

5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid;

2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid;

(Z,E)-5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic acid;


Chemical & Physical Properties:

Appearance: Deep red acicular crystal

Assay :≥99.00%

Density: 1.43 g/cm3

Boiling Point: 516.8℃ at 760 mmHg

Melting Point: 210-217℃

Flash Point: 266.4℃

Refractive Index: 1.705

Storage Condition: Store in original container in a cool dark place


Safety Information:

RIDADR: 2811

WGK Germany: 3

RTECS : XJ5131855

Hazard Class: 6.1

Packing Group: II


Epalrestat is a carboxylic acid derivative and a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy, which is one of the most common long-term complications in patients with diabetes mellitus. It reduces the accumulation of intracellular sorbitol which is believed to be the cause of diabetic neuropathy, retinopathy and nephropathy It is well tolerated, with the most commonly reported adverse effects being gastrointestinal issues such as nausea and vomiting, as well as increases in certain liver enzymes. Chemically, epalrestat is unusual in that it is a drug that contains a rhodanine group. Aldose reductase is the key enzyme in the polyol pathway whose enhanced activity is the basis of diabetic neuropathy. Aldose reductase inhibitors (ARI) target this enzyme. Out of the many ARIs developed, ranirestat and fidarestat are in the trial stage. Others have been discarded due to unacceptable adverse effects or weak efficacy. Epalrestat is the only ARI commercially available. It is easily absorbed into the neural tissue and inhibits the enzyme with minimum side effects.


If you are interested in our products or have any questions, please feel free to contact us!


Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.